Kevin Puylaert
CIK: 0002119354
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SOPHiA GENETICS SA
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Oct 5, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct185 shares at avg. $8.06$1K - Oct 5, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct31 shares at avg. $7.92$245.52 - Jul 6, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct47 shares at avg. $5.03$236.18 - Jul 6, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct138 shares at avg. $5.03$693.464 - Jul 6, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct31 shares at avg. $5.09$157.672 - May 19, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct33 shares at avg. $4.54$149.899 - Apr 20, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct33 shares at avg. $5.08$167.693 - Apr 6, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct30 shares at avg. $4.83$144.9 - Apr 6, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct548 shares at avg. $4.86$3K - Apr 6, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct46 shares at avg. $4.86$223.56 - Apr 2, 2026SOPH
SOPHiA GENETICS SA
Award(A)Direct56.5K shares- - Mar 31, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct3 shares at avg. $4.71$14.13 - Mar 19, 2026SOPH
SOPHiA GENETICS SA
Sale(S)Direct33 shares at avg. $4.76$157.08
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 5, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 185 | $8.06 | $1,491 | Direct |
| Oct 5, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 31 | $7.92 | $246 | Direct |
| Jul 6, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 47 | $5.03 | $236 | Direct |
| Jul 6, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 138 | $5.03 | $693 | Direct |
| Jul 6, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 31 | $5.09 | $158 | Direct |
| May 19, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 33 | $4.54 | $150 | Direct |
| Apr 20, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 33 | $5.08 | $168 | Direct |
| Apr 6, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 30 | $4.83 | $145 | Direct |
| Apr 6, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 548 | $4.86 | $2,663 | Direct |
| Apr 6, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 46 | $4.86 | $224 | Direct |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | Award(A) | 56,468 | - | $0 | Direct |
| Mar 31, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 3 | $4.71 | $14 | Direct |
| Mar 19, 2026 | SOPH SOPHiA GENETICS SA | Sale(S) | 33 | $4.76 | $157 | Direct |
1-13 of 13 transactions
About Puylaert Kevin
Puylaert Kevin (SEC CIK 0002119354) files insider reports with the SEC as Chief Sales Officer of SOPHiA GENETICS SA (SOPH).
Signal8 holds 10 ownership filings by Puylaert Kevin (1 Form 3, 9 Form 4), filed between Mar 18, 2026 and Oct 7, 2026. Those filings report 13 transactions, from Mar 19, 2026 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Puylaert Kevin's filings is in ROLLE.
Recent filings by Puylaert Kevin
- Oct 5, 2026: Open-market sales of SOPH shares (2 lines, Form 4, code S).
- Jul 6, 2026: Open-market sales of SOPH shares (3 lines, Form 4, code S).
- May 19, 2026: Open-market sale of SOPH shares (Form 4, code S).
- Apr 20, 2026: Open-market sale of SOPH shares (Form 4, code S).
- Apr 6, 2026: Open-market sales of SOPH shares (3 lines, Form 4, code S).
Other insiders filing for SOPHiA GENETICS SA (SOPH)
- Menu Philippe, Chief Medical Officer
- Xu Zhenyu, Chief Scientific Officer
- Camblong Jurgi, Executive Chairman
- Van Well Daan, Chief Legal Officer
- Valente Manuela, Chief People Officer
- Verma Abhimanyu, Chief Technology Officer